MarketPulse — Real-Time Financial News & Market Analysis

Soligenix wins EMA orphan drug designation backing for SGX945 treating Behçet's Disease, following positive Phase 2a results and prior FDA support.

Chubb proposes its 33rd consecutive annual dividend increase to $4.08 per share, reflecting strong financial confidence and commitment to shareholder returns.

Hims & Hers stock plunged 70% as GLP-1 market competition intensifies and growth slows. Despite challenges, company projects $2.8B 2026 revenue from diversified services.

PSEG raises annual dividend to $2.68 per share, marking 15 consecutive years of growth. The 6% increase reflects strong financial performance and shareholder commitment.

CrowdStrike shares fell 0.79% despite announcing an AI security partnership with VAST Data. Stock remains significantly below recent averages amid broader technical weakness.

Economist El-Erian warns AI market is a "rational bubble" with dangerous concentration among few companies, risking market correction and broader economic spillover effects.

AI sector hits cycle low with reduced speculation. Major tech firms like Meta, Amazon, Microsoft show real AI implementations, positioning for long-term recovery as adoption accelerates.

Tech giants have $662B in unreported data center leases that will soon hit balance sheets, potentially impacting key financial metrics and debt ratios as AI infrastructure expands.

MSC Income Fund declares $0.35 quarterly dividend plus $0.01 supplemental distribution, both payable May 1, 2026, from accumulated earnings.

BioCryst achieved historic profitability with ORLADEYO revenue surging 38% to $601.8 million. FDA approval for pediatric formulation and Astria acquisition expand HAE treatment portfolio.

Kyivstar's board, including VEON founder and Mike Pompeo, visited Ukraine to affirm operational commitment and reaffirm $1 billion investment plans through 2027 despite ongoing conflict.

Lantheus posted $1.54B in 2025 revenue but faces Q4 headwinds. The company plans to refocus on PET diagnostics while exploring options for radiotherapy assets, expecting four FDA approvals in 2026.

Ardagh Metal Packaging declares $0.10 quarterly dividend payable March 26, 2026. The metal packaging manufacturer continues returning capital to shareholders.

TScan completes Phase 1 trial enrollment and receives FDA clearance for two allogeneic cell therapy candidates, advancing its pipeline toward pivotal studies in 2026.

Upstream Bio will present expanded VIBRANT trial data on verekitug for chronic rhinosinusitis with nasal polyps at AAAAI 2026, including new efficacy analyses accounting for rescue therapy use.

Juvenescence completes Phase 1 trial of PAI-1 inhibitor MDI-2517 with positive safety results. Company expands leadership and plans Phase 2 study in late 2026.

Viatris reaffirms $0.48 annual dividend per share for 2026, declaring $0.12 quarterly payout. Marks sixth consecutive year of consistent shareholder distributions.

Occidental Petroleum stock surged in early 2026 after beating Q4 earnings expectations. Strong midstream operations and improving oil prices drove gains despite elevated debt levels.

TD Bank declared a $1.08 quarterly dividend per common share, payable April 30, 2026, demonstrating continued shareholder capital returns through regular distributions.

SanDisk stock surges post-spinoff from Western Digital, driven by AI data center demand for NAND flash storage and favorable industry pricing dynamics.